17122-60-0Relevant articles and documents
Method for synthesizing 7-nitroindole
-
Paragraph 0010; 0020, (2020/03/09)
The invention relates to a method for synthesizing 7-nitroindole. The method comprises the following steps: subjecting oxime generated by condensation of o-nitroaniline, hydroxylamine and chloral to anucleophilic substitution reaction in a solvent under the action of an acidic substance and a drying agent, and performing hydrolyzing under alkaline conditions to generate an oximido intermediate; preparing 7-nitroisatin from the oximido intermediate in the presence of an acidic substance; and subjecting the 7-nitroisatin to reduction in a solvent by a system consisting of sodium borohydride andzirconium chloride so as to obtain the product 7-nitroindole. According to the method for synthesizing the 7-nitroindole, the product is obtained through three steps, so a production cycle is remarkably shortened and productivity is improved; used materials are simple and easily-available, so cost is low; reaction conditions are mild; the method is suitable for industrial mass production; meanwhile, the system of sodium borohydride and zirconium tetrachloride is used for replacing borane in the reduction step, so virulent, flammable and combustible raw materials are avoided, and the method issafer and environmentally friendlier.
Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)-arene complexes of isomeric indolo[3,2-c ]quinoline - Piperazine hybrids
Filak, Lukas K.,Kalinowski, Danuta S.,Bauer, Theresa J.,Richardson, Des R.,Arion, Vladimir B.
supporting information, p. 6934 - 6943 (2014/07/22)
In this study, the indoloquinoline backbone and piperazine were combined to prepare indoloquinoline-piperazine hybrids and their ruthenium- and osmium-arene complexes in an effort to generate novel antitumor agents with improved aqueous solubility. In addition, the position of the metal-binding unit was varied, and the effect of these structural alterations on the aqueous solubility and antiproliferative activity of their ruthenium- and osmium-arene complexes was studied. The indoloquinoline-piperazine hybrids L1-3 were prepared in situ and isolated as six ruthenium and osmium complexes [(η6-p-cymene)M(L1-3)Cl]Cl, where L1 = 6-(4-methylpiperazin-1-yl)-N-(pyridin-2-yl-methylene)-11H-indolo[3,2-c] quinolin-2-N-amine, M = Ru ([1a]Cl), Os ([1b]Cl), L2 = 6-(4-methylpiperazin-1-yl)-N-(pyridin-2-yl-methylene)-11H-indolo[3,2-c] quinolin-4-N-amine, M = Ru ([2a]Cl), Os ([2b]Cl), L3 = 6-(4-methylpiperazin-1-yl)-N-(pyridin-2-yl-methylene)-11H-indolo[3,2-c] quinolin-8-N-amine, M = Ru ([3a]Cl), Os ([3b]Cl). The compounds were characterized by elemental analysis, one- and two-dimensional NMR spectroscopy, ESI mass spectrometry, IR and UV-vis spectroscopy, and single-crystal X-ray diffraction. The antiproliferative activity of the isomeric ruthenium and osmium complexes [1a,b]Cl-[3a,b]Cl was examined in vitro and showed the importance of the position of the metal-binding site for their cytotoxicity. Those complexes containing the metal-binding site located at the position 4 of the indoloquinoline scaffold ([2a]Cl and [2b]Cl) demonstrated the most potent antiproliferative activity. The results provide important insight into the structure-activity relationships of ruthenium- and osmium-arene complexes with indoloquinoline-piperazine hybrid ligands. These studies can be further utilized for the design and development of more potent chemotherapeutic agents.
DIHYDROOROTATE DEHYDROGENASE INHIBITORS
-
Page/Page column 61, (2010/11/03)
The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.
